GlassScriptPhysician profile
Garrettson Ellis
NPI 1336145317
$9,193.12
in general payments reported to CMS, 2019-2025
37 companies · $1,899 in 2025
The $1,899 reported for 2025 was more than what 86% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $849 · 2021: $1,055 · 2022: $1,152 · 2023: $1,540 · 2024: $1,530 · 2025: $1,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,913 · Education: $56.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,912.97 |
| Education | $56.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,057.88 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $912.39 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $742.73 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| United Therapeutics Corporation | $611.21 | 2019-2025 | Tyvaso, Orenitram, Tyvaso |
| Genentech USA, INC. | $605.55 | 2019-2025 | Xolair |
| Genzyme Corporation | $551.28 | 2019-2025 | |
| Insmed, INC. | $440.94 | 2019-2025 | Arikayce |
| Harmony Biosciences LLC | $407.18 | 2021-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $340.26 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $336.32 | 2019-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $322.68 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Mylan Specialty L.P. | $319.52 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $216.77 | 2019-2025 | Zerbaxa, Recarbrio, Winrevair |
| Amgen INC. | $143.76 | 2025 | Tezspire |
| Verona Pharma, INC. | $137.26 | 2025 | Ohtuvayre |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $122.56 | 2021-2025 | |
| La Jolla Pharmaceutical Company | $107.52 | 2020-2023 | Giapreza |
| Sunovion Pharmaceuticals INC. | $94.52 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.62 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $93.36 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.99 | 2021-2025 | Glassia |
| Tetraphase Pharmaceuticals, INC. | $70.48 | 2019-2020 | |
| Allergan, INC. | $50.01 | 2019-2020 | |
| Pfizer INC. | $46.04 | 2021-2022 | |
| Caris Mpi, INC. | $42.45 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $32.31 | 2021 | |
| Baxter Healthcare | $25.16 | 2024 | Hillrom - Monarch Airway Clearance System |
| Mallinckrodt Hospital Products INC. | $25.02 | 2020 | |
| Csl Behring | $21.89 | 2021 | |
| Pulmonx Corporation | $21.60 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Inogen, INC. | $18.50 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Lilly USA, LLC | $17.04 | 2025 | Zepbound |
| Ani Pharmaceuticals, INC. | $16.51 | 2022 | |
| Mallinckrodt Enterprises LLC | $15.16 | 2019 | |
| Advanced Respiratory, INC | $15.15 | 2021 | |
| Viatris Specialty LLC | $14.02 | 2025 | Yupelri |
| Cumberland Pharmaceuticals, INC. | $12.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrettson Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.